EGFR and prostate carcinoma: A cleaved domain 5 of high molecular weight kininogen (HK) is reported to bind to urokinase-type plasminogen activation receptor (uPAR) with high affinity and inhibit EGFR phosphorylation leading to significant reduction of cell migration and invasion in human prostate cancer cells [19].